Researchers affiliated with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) are set to unveil new findings from a diverse portfolio of clinical trials and translational research at the American Society of Clinical Oncology (ASCO) Annual Meeting. This major global conference will take place May 29 – June 2, 2026, at McCormick Place in Chicago, with the option for participants to join online.
Among the noteworthy clinical trial presentations from ECOG-ACRIN will be a late-breaking update from the STAMP study of Merkel cell carcinoma, building on prior findings that pembrolizumab immunotherapy appeared to reduce the risk of distant metastases when administered immediately after surgery. Attendees can also expect to hear primary results from studies in glioblastoma and non-small cell lung cancer, shedding light on these challenging malignancies.
Translational research abstracts will demonstrate emerging approaches in precision oncology, pushing the boundaries of current cancer care and offering hope for more personalized therapeutic strategies. Some leverage artificial intelligence (AI) to uncover patterns in tumor biology that may not be detectable through conventional approaches, informing risk stratification and treatment prediction.
Listed below are the presenters and their abstracts. Follow the links to the ASCO website for more information.
Immunotherapy for Aggressive Skin Cancer
Janice M. Mehnert, MD (Laura and Isaac Perlmutter Cancer Center at NYU Langone Health/New York University), will present a late-breaking abstract, Updated Outcomes From STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, A Phase 3 Trial: ECOG-ACRIN EA6174. Link to Abstract LBA9505 (embargoed until June 1 at 7:00 AM CST/8:00 AM EST).
Primary Results in Glioblastoma and Lung Cancer
Daniel P. Barboriak, MD (Duke University/Duke Cancer Institute), will orally present Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma: ECOG-ACRIN EAF151. Link to Abstract 2016 .
Jamie E. Chaft, MD (Memorial Sloan Kettering Cancer Center), will orally present Randomized Phase 3 Study of Nivolumab After Surgery and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (ECOG-ACRIN EA5142, ALCHEMIST). Link to Abstract 8000 .
Emerging Approaches in Precision Oncology
Sebastian R. Medina, MSc (Georgia Institute of Technology/Emory University), will orally present Spatial Transcriptomics-Guided Computational Pathology Model to Stratify Docetaxel Benefit in Metastatic Hormone-Sensitive Prostate Cancer: CHAARTED Trial (ECOG-ACRIN E3805). Link to Abstract 5002 .
Gil Shamai, PhD (Technion - Israel Institute of Technology), will orally present Clinical Utility of Discordances Between Histomorphology and Molecular Biomarkers in Precision Oncology. Link to Abstract 3005 .
AI-Driven Insights From the TAILORx Breast Cancer Trial
Magali lacroix-Triki, MD, PhD (Gustave Roussy), will orally present Incremental Prognostic Value of an AI-Derived Histology Signature Beyond the 21-Gene Recurrence Score: A Prospective-Retrospective Validation in TAILORx. Link to Abstract 554 .
Johan Hartman, MD, PhD (Karolinska Institutet), will present Prognostic Validation of Artificial Intelligence (AI)-Based Stratipath Breast Risk Stratification in TAILORx. Link to Abstract 555 .
Gil Shamai, PhD (Technion - Israel Institute of Technology), will present Predicting Chemotherapy Benefit in Premenopausal Breast Cancer Patients with Intermediate Genomic Scores. Link to Abstract 602 .
ctDNA and Tissue Profiling in the NCI-MATCH Trial
Rini Pauly, PhD, D.Phil (Frederick National Laboratory for Cancer Research), will present Comprehensive Genomic Profiling of Matched ctDNA and Tissue from Patients with Four Common Cancers Enrolled to the NCI-MATCH Trial. Link to Abstract 3045 .
Biomarkers and Clinical Factors Associated With Outcomes
James O. Jones, PhD, MRCP, MBBCh (University of Cambridge), will present Relationships Between Clinical Stage, Pathological Stage and Disease-Free Survival in Renal Cell Carcinoma Can Inform Future Neoadjuvant Study Design: ECOG-ACRIN EA8143 PROSPER Analysis. Link to Abstract 4540 .
Yvonne M. Saenger, MD (Albert Einstein College of Medicine), will present Validation of Melanoma Immune Profile to Predict Relapse-Free Survival in Stage 2–3 Melanoma on Adjuvant Interferon Trial (E1697). Link to Abstract e21596 .
Trials in Progress
Monika D. Joshi, MD (Penn State Cancer Institute), will present A Phase 3 Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti–PD-(L)1–Resistant Advanced Urothelial Cancer: ECOG-ACRIN EA8231. Link to Abstract TPS4641 .
Megan A. Baumgart, MD (Wilmot Cancer Institute/University of Rochester), will present A Randomized Phase 3 Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study. Link to Abstract TPS8674 .
John M. Kirkwood, MD (UPMC Hillman Cancer Center), will present A Phase 2 Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma: EA6232. Link to Abstract TPS9611 .
Maheswari Senthil, MD (Chao Family Comprehensive Cancer Center/University of California, Irvine), will present A Randomized Phase 2/3 Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis: The STOPGAP II Study—ECOG-ACRIN EA2234. Link to Abstract TPS4241 .
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a leading membership-based scientific organization known for advancing precision oncology through innovative clinical trials. Notable trials include TAILORx, NCI-MATCH, ComboMATCH, and many others that integrate cutting-edge genomic approaches. The organization has an expansive membership of over 1,400 hospitals and cancer centers across the United States and worldwide, involving approximately 21,000 research professionals and advocates. Its research is funded primarily by the National Cancer Institute, one of the United States’ National Institutes of Health. To learn more, visit www.ecog-acrin.org and follow us on X @EAonc , Facebook , LinkedIn , YouTube , and Instagram .